Literature DB >> 10216113

Prevention of transfusion-associated graft-versus-host disease by photochemical treatment.

J A Grass1, T Wafa, A Reames, D Wages, L Corash, J L Ferrara, L Lin.   

Abstract

Photochemical treatment (PCT) with the psoralen S-59 and long wavelength ultraviolet light (UVA) inactivates high titers of contaminating viruses, bacteria, and leukocytes in human platelet concentrates. The present study evaluated the efficacy of PCT to prevent transfusion-associated graft-versus-host disease (TA-GVHD) in vivo using a well-characterized parent to F1 murine transfusion model. Recipient mice in four treatment groups were transfused with 10(8) splenic leukocytes. (1) Control group mice received syngeneic splenic leukocyte transfusions; (2) GVHD group mice received untreated allogeneic splenic leukocytes; (3) gamma radiation group mice received gamma irradiated (2,500 cGy) allogeneic splenic leukocytes; and (4) PCT group mice received allogeneic splenic leukocytes treated with 150 micromol/L S-59 and 2.1 J/cm2 UVA. Multiple biological and clinical parameters were used to monitor the development of TA-GVHD in recipient mice over a 10-week posttransfusion observation period: peripheral blood cell levels, spleen size, engraftment by donor T cells, thymic cellularity, clinical signs of TA-GVHD (weight loss, activity, posture, fur texture, skin integrity), and histologic lesions of liver, spleen, bone marrow, and skin. Mice in the control group remained healthy and free of detectable disease. Mice in the GVHD group developed clinical and histological lesions of TA-GVHD, including pancytopenia, marked splenomegaly, wasting, engraftment with donor derived T cells, and thymic hypoplasia. In contrast, mice transfused with splenic leukocytes treated with (2,500 cGy) gamma radiation or 150 micromol/L S-59 and 2.1 J/cm2 UVA remained healthy and did not develop detectable TA-GVHD. Using an in vitro T-cell proliferation assay, greater than 10(5.1) murine T cells were inactivated by PCT. Therefore, in addition to inactivating high levels of pathogenic viruses and bacteria in PC, these data indicate that PCT is an effective alternative to gamma irradiation for prevention of TA-GVHD.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10216113

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  16 in total

Review 1.  Infectious risks associated with the transfusion of blood components and pathogen inactivation in Japan.

Authors:  Masahiro Satake
Journal:  Int J Hematol       Date:  2004-11       Impact factor: 2.490

Review 2.  The hazards of blood transfusion in historical perspective.

Authors:  Harvey J Alter; Harvey G Klein
Journal:  Blood       Date:  2008-10-01       Impact factor: 22.113

3.  11 Adverse Reactions.

Authors: 
Journal:  Transfus Med Hemother       Date:  2009       Impact factor: 3.747

4.  Apoptotic signaling through Fas and TNF receptors ameliorates GVHD in mobilized peripheral blood grafts.

Authors:  K Mizrahi; I Yaniv; S Ash; J Stein; N Askenasy
Journal:  Bone Marrow Transplant       Date:  2014-02-24       Impact factor: 5.483

5.  Human umbilical cord blood-derived stromal cells, a new resource in the suppression of acute graft-versus-host disease in haploidentical stem cell transplantation in sublethally irradiated mice.

Authors:  Cheng Zhang; Xing-Hua Chen; Xi Zhang; Lei Gao; Pei-Yan Kong; Xian-gui Peng; Xue Liang; Li Gao; Yi Gong; Qing-Yu Wang
Journal:  J Biol Chem       Date:  2011-02-24       Impact factor: 5.157

6.  Reduced MHC alloimmunization and partial tolerance protection with pathogen reduction of whole blood.

Authors:  Rachael P Jackman; Marcus O Muench; Heather Inglis; John W Heitman; Susanne Marschner; Raymond P Goodrich; Philip J Norris
Journal:  Transfusion       Date:  2016-11-18       Impact factor: 3.157

7.  IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease.

Authors:  David Polchert; Justin Sobinsky; Gw Douglas; Martha Kidd; Ada Moadsiri; Eduardo Reina; Kristyn Genrich; Swati Mehrotra; Suman Setty; Brett Smith; Amelia Bartholomew
Journal:  Eur J Immunol       Date:  2008-06       Impact factor: 5.532

8.  Understanding loss of donor white blood cell immunogenicity after pathogen reduction: mechanisms of action in ultraviolet illumination and riboflavin treatment.

Authors:  Rachael P Jackman; John W Heitman; Susanne Marschner; Raymond P Goodrich; Philip J Norris
Journal:  Transfusion       Date:  2009-08-04       Impact factor: 3.157

9.  Human mesenchymal stem cells suppress donor CD4(+) T cell proliferation and reduce pathology in a humanized mouse model of acute graft-versus-host disease.

Authors:  L M Tobin; M E Healy; K English; B P Mahon
Journal:  Clin Exp Immunol       Date:  2013-05       Impact factor: 4.330

Review 10.  Chemical and biological mechanisms of pathogen reduction technologies.

Authors:  Janna M Mundt; Lindsay Rouse; Jeroen Van den Bossche; Raymond P Goodrich
Journal:  Photochem Photobiol       Date:  2014-08-20       Impact factor: 3.421

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.